Current use of drugs for osteoporosis in Korea.

Park, Hyoung Moo

doi:2010.53.2.152

Search: Korean J Obstet Gynecol Search

CLOSE

Obstet Gynecol Sci > Volume 53(2); 2010 > Article

Original Article

Korean Journal of Obstetrics & Gynecology 2010;53(2):152-159.
DOI: https://doi.org/10.5468/kjog.2010.53.2.152 Published online February 1, 2010.

Current use of drugs for osteoporosis in Korea.

Hyoung Moo Park

Department of Obstetrics and Gynecology, Chung-Ang University College of Medicine, Yong-San Hospital, Seoul, Korea. hmpark@hananet.net

Abstract

OBJECTIVE
Postmenopausal osteoporosis is a common skeletal disease with serious consequences due to fracture, leading to increased morbidity and mortality. This study was carried out to evaluate the changes of national osteoporosis markets during the last 5 years and to estimate the trends of national osteoporosis market in the future. METHODS: The use of the medications for osteoporosis treatment was evaluated in terms of sales of drugs for osteoporosis treatment. The sales audit of drugs for osteoporosis treatment from Intercontinental Marketing Services (IMS) were used to analyse the sales of specific drugs. RESULTS: The total national osteoporosis market has been increased progressively and markedly during the last 5 years and was valued at 167.4 billion Korean won (KRW) in 2008. The use of hormone therapy was decreased markedly by 40% after reporting of WHI results and the reduction of hormone therapy has been continuing during the recent 5 years. The market size of the non-hormonal osteoporosis drugs has been grown by 73% during the last 5 years and was valued at 134.5 billion KRW in 2008. This non-hormonal drug market was dominated by bisphosphonates. which account for over 80% of total sales. The use of bisphosphonates and active vitamin D metabolites has been increasing but raloxifene and calcitonin, decreasing. CONCLUSION: The survery of recent national osteoporosis market using IMS sales audit showed that the use of drugs for osteoporosis treatment has been markedlly increasing during last 5 years from 2004 to 2008. This has been attributed to non-horomonal pharmacological drugs, especially bisphosphonate.

Key Words: Osteoporosis, Medications, Sales market, Bisphosphonate

TOOLS

PDF Links
Full text via DOI
Download Citation

Share :

METRICS

10 Crossref
1,293 View
20 Download

Related articles in Obstet Gynecol Sci

Current techniques used to perform surgery for anterior and posterior vaginal wall prolapse in South Korea2022 May;65(3)

Current Status of Assisted Reproductive Technology in Korea for 1994.1998 January;41(1)

A Statistical Analysis of Risk Factors for Osteoporosis in Menopausal Women.1998 March;41(3)

Current Status of Assisted Reproductive Technology in Korea, 1997.1999 October;42(10)

Clinical Usefulness of Alendronate for Osteoporosis in Postmenopausal women.2000 November;43(11)

ABOUT

ARTICLE & TOPICS

Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES

POLICY

FOR CONTRIBUTORS

Editorial Office: 4th Floor, 36 Gangnam-daero 132-gil, Gangnam-gu, Seoul 06044, Korea.
Tel: +82-2-2266-7238 Fax: +82-2-3445-2440 E-mail: journal@ogscience.org